Lung Cancer Clinical Trials & Research at Providence Medical Group
The two main types of lung cancer are non-small cell lung cancer and small
cell lung cancer. The types are based on the way the cells look under
a microscope. Non-small cell lung cancer is much more common than small
cell lung cancer. Tobacco smoking is the most common cause of lung cancer.
Providence Medical Group is currently enrolling patients for the following
lung cancer clinical trials:
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients
with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Treatment agent: MRTX849 + pembrolizumab
PI:
Manasa Vulchi, MD
Study Coordinator: Tracy Foster
Resources and Links:
clinicaltrials.gov NCT No: NCT04613596
Sponsor: Mirati Therapeutics, Inc.
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants
With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)
Treatment agent: Zimberelimab with or without domvanalimab and/or etrumadenant
PI:
Ian Anderson, MD
Study Coordinator: Camille Shaffer
Resources and Links:
clinicaltrials.gov NCT No: NCT04262856
Sponsor: Arcus Biosciences, Inc.
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed
by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell
Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Treatment agent: Pembrolizumab + chemotherapy/olaparib OR chemotherapy
+ durvalumab
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT04380636
Sponsor: Merck Sharp & Dohme Corp.
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled
Study to Determine the Efficacy of Adjuvant Durvalumab in Combination
with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC
(MeRmaiD-1)
Treatment agent: Durvalumab + chemotherapy
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT04385368
Sponsor: AstraZeneca
A Phase III, Open-label, Randomized Study of Osimertinib with or without
Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients
with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally
Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)
Treatment agent: Osimertinib with or without platinum-based chemotherapy
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT04035486
Sponsor: AstraZeneca
Phase 2 Platform Study in Patients with advanced non-small lung cancer
who progressed on First Line Osimertinib therapy (ORCHARD)
Treatment agent: Osimertinib
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT03944772
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase
Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo
with Pembrolizumab and Chemotherapy in First-Line, Metastic KEAP1/NRF2-Mutated,
Nonsquamous, Non-Small Cell Lung Cancer (KEAPSAKE CX-839-014)
Treatment agent: Telaglenastat/ placebo + SOC
PI:
Ian Anderson, MD
Study Coordinator: Teresa
Resources and Links:
clinicaltrials.gov No: NCT04265534
Small Cell Lung Cancer
Study of Durvalumab + Tremelimuab, Durvalumab, and Placebo in Limited Stage
Small- Cell Lung Cancer in Patients who Have Not progressed following
concurrent chemoradiation therapy (ADRIATIC)
Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT03703297
Seer-020201 (Pulmonary Nodules)
Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI:
Manasa Vulchi, MD
Study Coordinator: Melissa
NCT – NA